Tags

Type your tag names separated by a space and hit enter

Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes.
Diabetes 2016; 65(12):3744-3753D

Abstract

We examined associations of advanced glycation end products (AGEs) with renal function loss (RFL) and its structural determinants in American Indians with type 2 diabetes. Data were from a 6-year clinical trial that assessed renoprotective efficacy of losartan. Participants remained under observation after the trial concluded. Glomerular filtration rate (GFR) was measured annually. Kidney biopsies were performed at the end of the trial. Five AGEs were measured in serum collected at enrollment and at kidney biopsy. RFL was defined as ≥40% decline of measured GFR from baseline. Of 168 participants (mean baseline age 41 years, HbA1c 9.2%, GFR 164 mL/min, and albumin-to-creatinine ratio 31 mg/g), 104 reached the RFL end point during median follow-up of 8.0 years. After multivariable adjustment, each doubling of carboxyethyl lysine (hazard ratio [HR] 1.60 [95% CI 1.08-2.37]) or methylglyoxal hydroimidazolone (HR 1.30 [95% CI 1.02-1.65]) concentration was associated with RFL. Carboxyethyl lysine, carboxymethyl lysine, and methylglyoxal hydroimidazolone correlated positively with cortical interstitial fractional volume (partial r = 0.23, P = 0.03; partial r = 0.25, P = 0.02; and partial r = 0.31, P = 0.003, respectively). Glyoxyl hydroimidazolone and methylglyoxal hydroimidazolone correlated negatively with total filtration surface per glomerulus (partial r = -0.26, P = 0.01; and partial r = -0.21, P = 0.046, respectively). AGEs improve prediction of RFL and its major structural correlates.

Authors+Show Affiliations

Phoenix Epidemiology and Clinical Research Branch, Phoenix, AZ. CHU Poitiers, University of Poitiers, Clinical Investigation Center, INSERM CIC1402, Poitiers, France.Phoenix Epidemiology and Clinical Research Branch, Phoenix, AZ.PreventAGE Health Care, Lebanon, NH.Phoenix Epidemiology and Clinical Research Branch, Phoenix, AZ.Phoenix Epidemiology and Clinical Research Branch, Phoenix, AZ.Phoenix Epidemiology and Clinical Research Branch, Phoenix, AZ.Department of Pediatrics, University of Southern California Keck School of Medicine, Children's Hospital Los Angeles, Los Angeles, CA.Department of Pediatrics and Medicine, University of Minnesota, Minneapolis, MN.Southwest Kidney Institute, Phoenix, AZ.Phoenix Epidemiology and Clinical Research Branch, Phoenix, AZ rnelson@nih.gov.PreventAGE Health Care, Lebanon, NH.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

27609106

Citation

Saulnier, Pierre-Jean, et al. "Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes." Diabetes, vol. 65, no. 12, 2016, pp. 3744-3753.
Saulnier PJ, Wheelock KM, Howell S, et al. Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes. Diabetes. 2016;65(12):3744-3753.
Saulnier, P. J., Wheelock, K. M., Howell, S., Weil, E. J., Tanamas, S. K., Knowler, W. C., ... Beisswenger, P. J. (2016). Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes. Diabetes, 65(12), pp. 3744-3753.
Saulnier PJ, et al. Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes. Diabetes. 2016;65(12):3744-3753. PubMed PMID: 27609106.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes. AU - Saulnier,Pierre-Jean, AU - Wheelock,Kevin M, AU - Howell,Scott, AU - Weil,E Jennifer, AU - Tanamas,Stephanie K, AU - Knowler,William C, AU - Lemley,Kevin V, AU - Mauer,Michael, AU - Yee,Berne, AU - Nelson,Robert G, AU - Beisswenger,Paul J, Y1 - 2016/09/08/ PY - 2016/03/07/received PY - 2016/09/05/accepted PY - 2016/9/10/pubmed PY - 2017/6/1/medline PY - 2016/9/10/entrez SP - 3744 EP - 3753 JF - Diabetes JO - Diabetes VL - 65 IS - 12 N2 - We examined associations of advanced glycation end products (AGEs) with renal function loss (RFL) and its structural determinants in American Indians with type 2 diabetes. Data were from a 6-year clinical trial that assessed renoprotective efficacy of losartan. Participants remained under observation after the trial concluded. Glomerular filtration rate (GFR) was measured annually. Kidney biopsies were performed at the end of the trial. Five AGEs were measured in serum collected at enrollment and at kidney biopsy. RFL was defined as ≥40% decline of measured GFR from baseline. Of 168 participants (mean baseline age 41 years, HbA1c 9.2%, GFR 164 mL/min, and albumin-to-creatinine ratio 31 mg/g), 104 reached the RFL end point during median follow-up of 8.0 years. After multivariable adjustment, each doubling of carboxyethyl lysine (hazard ratio [HR] 1.60 [95% CI 1.08-2.37]) or methylglyoxal hydroimidazolone (HR 1.30 [95% CI 1.02-1.65]) concentration was associated with RFL. Carboxyethyl lysine, carboxymethyl lysine, and methylglyoxal hydroimidazolone correlated positively with cortical interstitial fractional volume (partial r = 0.23, P = 0.03; partial r = 0.25, P = 0.02; and partial r = 0.31, P = 0.003, respectively). Glyoxyl hydroimidazolone and methylglyoxal hydroimidazolone correlated negatively with total filtration surface per glomerulus (partial r = -0.26, P = 0.01; and partial r = -0.21, P = 0.046, respectively). AGEs improve prediction of RFL and its major structural correlates. SN - 1939-327X UR - https://www.unboundmedicine.com/medline/citation/27609106/Advanced_Glycation_End_Products_Predict_Loss_of_Renal_Function_and_Correlate_With_Lesions_of_Diabetic_Kidney_Disease_in_American_Indians_With_Type_2_Diabetes_ L2 - http://diabetes.diabetesjournals.org/cgi/pmidlookup?view=long&pmid=27609106 DB - PRIME DP - Unbound Medicine ER -